SCHEDULE 13G/A: Phoenix Venture Partners Reduces Stake in Absci Corporation Below 5%
Beneficial Ownership Report
Phoenix Venture Partners II, LP and its general partner have reported a reduction in their beneficial ownership of Absci Corporation's common stock to 3.7%, falling below the 5% threshold.
Summary
- Phoenix Venture Partners II, LP and its general partner, Phoenix General Partner II LLC, have filed an Amendment No. 4 to Schedule 13G regarding their beneficial ownership in Absci Corporation.
- As of March 31, 2025, the Reporting Persons collectively beneficially own 4,745,115 shares of Absci Corporation's common stock.
- This ownership represents 3.7% of the total outstanding common stock of Absci Corporation.
- The percentage is calculated based on 127,333,887 shares of common stock issued and outstanding as of February 28, 2025, as reported in Absci Corporation's Form 10-K for the fiscal year ended December 31, 2024.
- The filing indicates that the Reporting Persons now hold less than 5% of the class, which is a key threshold for beneficial ownership reporting.
Sentiment
Score: 4
Explanation: The sentiment is moderately negative due to a significant investor reducing their stake below the 5% threshold, which can be interpreted as a loss of confidence or a strategic exit.
Negatives
- A significant institutional investor, Phoenix Venture Partners II, LP, has reduced its beneficial ownership in Absci Corporation to below the 5% threshold, which can be interpreted as a decrease in conviction or a strategic divestment.
Risks
- The reduction in a significant investor's stake could signal potential concerns about the company's future performance or valuation, potentially leading to negative market sentiment.
Future Outlook
The document does not contain any forward-looking statements or guidance from Absci Corporation or the reporting entities regarding future operations or financial performance.
Industry Context
This filing is a standard disclosure of a change in beneficial ownership by an institutional investor in a publicly traded biotechnology company. A reduction in stake by a venture capital firm can sometimes reflect a shift in investment strategy or a realization of gains/losses, which is common in the lifecycle of venture investments in public companies.
Stakeholder Impact
- Shareholders: The reduction in a significant investor's stake could lead to increased selling pressure or a decrease in investor confidence, potentially impacting share price.
Key Dates
| Date | Description |
|---|---|
| 2024-12-31 | Fiscal year end for Absci Corporation's Form 10-K, which reported outstanding shares. |
| 2025-02-28 | Date as of which 127,333,887 shares of Common Stock were reported as issued and outstanding in Absci Corporation's 10-K. |
| 2025-03-31 | Date of event which requires the filing of this Schedule 13G statement, reflecting the beneficial ownership. |
| 2025-05-15 | Date the Schedule 13G Amendment No. 4 was signed and filed. |
Recommendation
holdKeywords
Absci Corporation, Phoenix Venture Partners, Schedule 13G, Beneficial Ownership, Common Stock, SEC Filing, Institutional Investor, Stake Reduction, Biotechnology, Investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.